Results 301 to 308 of about 198,039 (308)

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Nature Medicine, 2019
Paolo A Ascierto, Pier Francesco Ferrucci, Victoria Atkinson   +2 more
exaly  

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Nature Medicine, 2020
Priscilla K Brastianos, Justine V Cohen, Sara M Tolaney   +2 more
exaly  

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Clinical Oncology, 2020
Richard S Finn, Masafumi Ikeda, Andrew X Zhu   +2 more
exaly  

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Lancet Oncology, The, 2018
Andrew X Zhu, Richard S Finn, Julien Edeline   +2 more
exaly  

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Lancet, The, 2019
Christophe Le Tourneau, Lisa F Licitra
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Journal of Clinical Oncology, 2019
Matthew D Hellmann, Naiyer A Rizvi, Natasha B Leighl   +2 more
exaly